Delineating the non-conventional MHC class I and class II peptidome of influenza
Delineating the non-conventional MHC class I and class II peptidome of influenza
批准号:
10041955
负责人:
Laurence Crane Eisenlohr
金额:
$26.67万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-01 至 2022-05-31
关键词:
Antigen-Presenting CellsAntigensAutoantigensAutoimmune DiseasesBiological AssayCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCell physiologyCellsCellular biologyCodon NucleotidesCollaborationsCommunicable DiseasesComplexCoupledDataDatabasesDevelopmentEndoplasmic Reticulum Degradation PathwayEpitope MappingEpitopesExtracellular SpaceFlow CytometryFrequenciesFutureGene ExpressionGenetic TranscriptionGenomeGoalsHistocompatibility Antigens Class IIHost DefenseImmuneImmune systemImmunityIn VitroInfectionInfectious AgentInfluenzaInvestigationLightLiquid ChromatographyMHC Class I GenesMainstreamingMajor Histocompatibility ComplexMalignant NeoplasmsMass Spectrum AnalysisMediatingMethodsModelingModificationMusNatureOligonucleotidesOutcomePeptidesPeripheralPhosphorylationPost-Translational Protein ProcessingPrevalenceProductionProteinsProteomePublicationsPublishingRNARNA ProcessingRNA SplicingReading FramesResearchRibosomal FrameshiftingSite-Directed MutagenesisSurface AntigensSystemT cell responseT-Cell ActivationT-LymphocyteTechniquesTerminator CodonTestingTherapeuticTissuesTranslatingTranslation InitiationTranslationsTumor AntigensWorkadaptive immune responseantigen processingcytokinefluglycosylationimmunogenicityinterestmouse modelmulticatalytic endopeptidase complexpathogenpolypeptideprophylacticresponsesynthetic peptidetandem mass spectrometryvirtual
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
A cornerstone of adaptive immune responses to infectious agents, cancers and self-tissues is the activation of
CD4+ and CD8+ T cells by antigen-derived peptides (epitopes) complexed with Major Histocompatibility Complex
class II and class I molecules (MHC-II and -I), respectively. Accordingly, identification of T cell-activating peptides
is frequently a critical step in the development of rational prophylactic and therapeutic strategies. Most methods
for identification are guided by the prevailing view that peptides are excerpted from the products of conventional
transcription, RNA processing and translation. However, we and other labs have demonstrated that MHC-I- and
-II-bound peptides can be derived from a wide array of non-canonical mechanisms, including initiation of
translation in an alternative reading frame, initiation at a non-AUG codon, co-translational frameshifting, and
proteasome-mediated post-translational peptide splicing. Currently, non-conventional epitopes are of peripheral
interest, perhaps because many fundamental questions concerning their significance remain unanswered. We
do not understand: 1) the fraction of all presented peptides that are non-conventional, 2) whether all the
mechanisms underlying non-canonical peptide production have been described, 3) the relative frequencies with
which different mechanisms produce non-conventional epitopes, 4) the extent to which non-conventional
epitopes drive T cell responses to infectious agents, cancers and self-antigens, and, 5) the prevalence of MHC-
II-presented non-canonical peptides, most examples thus far being MHC-I-restricted. With respect to question
4, a recent publication and our preliminary data indicate that non-canonical peptides can drive strong,
immunodominant T cell responses. With respect to question 5, the Eisenlohr lab has developed a model of MHC-
II-restricted peptide production that is far more complex than generally envisioned. Thus, many of the
mechanisms that produce MHC-I-restricted non-conventional epitopes should apply to MHC-II. Through a highly
complementary collaboration between the Eisenlohr and Ternette labs, via cutting-edge mass spectrometry,
well-developed immune recognition assays, and an array of methods to identify mechanisms underlying non-
conventional epitope expression, we will test the hypothesis that both MHC-I and MHC-II non-canonical epitopes,
produced by a variety of mechanisms, drive a substantial portion of the TCD8+ and TCD4+ responses to influenza.
In addition to potentially uncovering new fundamental cell biology, outcomes could substantially alter the view of
host defenses against a high priority infectious disease, pointing to new prophylactic and therapeutic strategies.
In addition, we envision the work launching several lines of future investigation, including: 1) assessing the
protective capacities of non-conventional epitope-specific T cells, 2) elucidating the antigen processing
machinery that produces non-conventional epitopes, 3) identifying the determinants of immunodominance and
functionality with respect to conventional vs non-conventional epitopes, and 4) carrying out similar analyses with
other infectious agents, cancers and autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein
-
批准号:10364738
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2021
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein
-
批准号:10205831
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2021
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Delineating the non-conventional MHC class I and class II peptidome of influenza
-
批准号:10171775
-
项目类别:
-
资助金额:$21.0万
-
财政年份:2020
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Defining the MHC-II processing and presentation landscape of HIV-1
-
批准号:9762836
-
项目类别:
-
资助金额:$21.5万
-
财政年份:2018
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses
-
批准号:9198974
-
项目类别:
-
资助金额:$56.46万
-
财政年份:2015
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses
-
批准号:9108850
-
项目类别:
-
资助金额:$56.46万
-
财政年份:2015
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Alternative MHCII Processing of Influenza Virus Proteins
-
批准号:8764161
-
项目类别:
-
资助金额:$45.86万
-
财政年份:2014
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Class II Processing and Presentation During Secondary Responses to Influenza
-
批准号:8823195
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2014
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Alternative MHCII Processing of Influenza Virus Proteins
-
批准号:9280869
-
项目类别:
-
资助金额:$54.61万
-
财政年份:2014
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Alternative MHCII Processing of Influenza Virus Proteins
-
批准号:9061590
-
项目类别:
-
资助金额:$61.84万
-
财政年份:2014
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Alternative MHCII Processing of Influenza Virus Proteins
-
批准号:9198297
-
项目类别:
-
资助金额:$38.53万
-
财政年份:2014
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Alternative Pathways for CD4+ T Cell Epitope Generation from Influenza Antigens
-
批准号:8706548
-
项目类别:
-
资助金额:$51.93万
-
财政年份:2013
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
The RET/PTC3 Oncogene: Antigenic and Inflammatory Properties
-
批准号:8503600
-
项目类别:
-
资助金额:$18.21万
-
财政年份:2012
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
The RET/PTC3 Oncogene: Antigenic and Inflammatory Properties
-
批准号:8364430
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2012
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design
-
批准号:8415820
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2012
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design
-
批准号:9189145
-
项目类别:
-
资助金额:$28.42万
-
财政年份:2012
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design
-
批准号:8319915
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2012
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes
-
批准号:7746211
-
项目类别:
-
资助金额:$35.16万
-
财政年份:2009
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Dynamics of tolerance induction to tumor associated antigens
-
批准号:7512068
-
项目类别:
-
资助金额:$20.86万
-
财政年份:2008
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
Dynamics of tolerance induction to tumor associated antigens
-
批准号:7645028
-
项目类别:
-
资助金额:$17.38万
-
财政年份:2008
-
负责人:Laurence Crane Eisenlohr
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: